Regulation & Compliance
Coverage of the regulatory environment around research: FDA, EMA and MHRA actions, clinical-trial regulation, research security and export control, data protection and privacy enforcement, and laboratory safety enforcement. Accuracy on citations and effective dates is non-negotiable on this beat, since readers act on it operationally.
Beats in this category
- Clinical Trial Regulation
Rules governing trial conduct, registration, and results reporting — ICH guideline revisions, national trial regulations, transparency enforcement, and reporting-compliance finding…
- Data Protection & Privacy
Privacy regulation as it applies to research data — GDPR enforcement, HIPAA developments, international transfer mechanisms, and consent requirements for secondary data use.…
- FDA, EMA & Regulator Actions
Regulatory agency guidance, approvals, warning letters, and inspection findings relevant to research operations, with attention to effective dates and what is actually binding vers…
- Lab Safety & Biosafety Enforcement
Laboratory safety incidents, OSHA and biosafety enforcement actions, containment breaches, and the regulatory responses that follow.…
- Research Security & Export Control
Foreign-influence policy, disclosure requirements, export control (ITAR/EAR) as applied to research, and enforcement actions against researchers and institutions.…
All coverage (37)
- FDA’s 2026 Unified Agenda: Trial Reform Docket
FDA’s July 2026 Unified Agenda lists a dozen new proposed rules on clinical trials, Phase 1 IND, DTC ads, and CRL disclosure beyond the IND pilot.…
- HHS OIG RFI: AKS Safe Harbors for Trial Pay
HHS OIG is asking whether the Anti-Kickback Statute needs a new safe harbor for paying clinical trial participants. Comments on the RFI are due August 24, 2026.…
- FDA’s Elsa 4.0 and HALO: Sponsor Impact
FDA shipped Elsa 4.0 and the HALO data platform in May 2026 — an internal AI upgrade, not a sponsor-facing one. Here is what changed and what did not.…
- EMA Draft Guidance on Trials During Emergencies
EMA’s draft guidance on running clinical trials during public health emergencies closed for comment April 30, 2026. Finalisation is still pending.…
- FDA RFI: AI-Enabled Early-Phase Trials Pilot
FDA’s April 2026 RFI sought input on an AI-enabled early-phase trials pilot. Comment window closed June 29, 2026 — here’s what it covered.…
- FDA CMC Flexibility for Cell & Gene Therapy
FDA eased CMC expectations for cell and gene therapy BLAs on Jan 11, 2026 — finalized in May, extended to genome editing in June.…
- EU Biotech Act’s Proposed CTR-GDPR Changes
The EU’s proposed Biotech Act (Commission proposal adopted 16 December 2025, not yet enacted) would revise Clinical Trials Regulation Article 93 to align it with GDPR, naming sponsors and investigator…
- FDA Cites Bioequivalence Site for Consent Timing
An FDA warning letter dated July 10, 2026, cites a bioequivalence-trial investigator tied to an Alembic Pharmaceuticals facility for obtaining informed consent after study procedures had already begun…
- EU’s Research Security Monitor 2025, Explained
On Feb 27, 2026, the EU Commission issued its first Research Security Monitor plus a Council Recommendation on science diplomacy, adopted May 29, 2026.…
- FDA’s New Guidance on Trial Eligibility Criteria
FDA’s Dec. 2025 guidance pushes sponsors to justify restrictive eligibility criteria, distinct from and broader than the FDORA diversity action plan mandate.…
- Texas HB 127: Research-Security Deadline Hits
Texas HB 127 (not SB 1565) sets an August 2026 research-security certification deadline for Texas public university boards.…
- GAO: Research-Security Screening Needs Bias Review
GAO: 5 top research-funding agencies havent assessed whether security screening risks discriminating against Chinese and Asian-descent scientists.…
- DETERRENT Act Stalls in the Senate
The House-passed DETERRENT Act would cut the Section 117 foreign-gift threshold to $50,000. A 26-group coalition pushed the stalled Senate bill in May 2026.…
- BIOSECURE Act Becomes Law for Biotech Research
BIOSECURE Act became law Dec 18, 2025 (NDAA Sec. 851), restricting federal contracts and grants tied to designated biotechnology companies of concern.…
- The SAFE Research Act Was Dropped From the FY2026 NDAA: Why the Research Community’s Pushback Succeeded
The SAFE Research Act would have cut federal funding over ‘hostile foreign entity’ ties. University pushback got it struck from the FY2026 NDAA.…
- EDPB Guidelines 1/2026: Draft GDPR Rules for Research Data Now Under Review
The EDPB’s draft Guidelines 1/2026, published 15 April 2026, set out a six-factor test for “scientific research” under GDPR and detail Article 89 safeguards, legal bases, and a restrictive line on dat…
- FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program
FDA’s Commissioner’s National Priority Voucher (CNPV) pilot promises a one-to-two-month review for drugs meeting national health priorities. Here’s how it differs from statutory Priority Review Vouche…
- Health Canada’s 2026 Clinical Trial Overhaul
Health Canada’s draft Clinical Trials Regulations and its April 2026 ICH E6(R3) adoption mark Canada’s biggest trial-oversight overhaul in decades.…
- FDA Revises Draft Guidance on Substantial Evidence of Effectiveness
FDA’s June 22, 2026 revised draft guidance clarifies when a single adequate and well-controlled trial plus confirmatory evidence can satisfy the substantial-evidence-of-effectiveness standard for drug…
- FDA’s 2026 Draft Guidance on Bayesian Methodology in Clinical Trials: What It Sets Out
FDA published draft guidance Jan. 12, 2026 setting expectations for Bayesian primary-analysis designs in drug/biologic trials. Comments closed March 13, 2026.…
- RAPID Coverage Pathway: CMS and FDA’s New Fast Track for Breakthrough Devices
CMS and FDA launched RAPID on April 23, 2026, targeting Medicare coverage within 60-90 days of FDA authorization for breakthrough devices, pausing TCET for new candidates.…
- FDA Finalizes Psychedelic Drug Trial Guidance
FDA’s final guidance sets trial-design rules for psychedelic drug studies, addressing functional unblinding and abuse-potential testing.…
- FDA Finalizes Corticosteroid, OTC Meeting Rules
On July 14, 2026, FDA finalized guidances on generic topical corticosteroid bioequivalence testing and formal FDA meetings for OTC monograph drug sponsors.…
- Rutgers Dean Jacqueline Mattis Faces Ethics Probe Over Payments to Her Own Retreat Company
Rutgers University is investigating whether payments its own units made to Dean Jacqueline Mattis’s writing-retreat company, Easton’s Nook, violate New Jersey conflict-of-interest law. Reported totals…
- Südhof Calls for an ‘FDA for Journals’ at Lindau
Nobel laureate Thomas Südhof told Lindau 2026 that publishing is unregulated, dismissed COPE as self-serving, and urged a government “FDA for journals.”…
- FDA’s Revised Master Protocol Draft Guidance: What Basket, Umbrella, and Platform Trial Teams Need to Know
FDA reopened comment on its master protocol draft guidance in June 2026, adding new basket-trial recommendations. Comments are open through August 24, 2026.…
- Export Control Enforcement Trends 2026: What BIS’s Record Penalties Reveal
BIS’s 2026 settlements, led by a record $252.5M Applied Materials case, reveal what triggers export-control violations for research institutions.…
- COGR’s June 2026 Meeting: GAO Briefs Members on Research Security
COGR’s June 2026 meeting included a GAO briefing flagging research security as a top oversight area. What’s confirmed, and what it means for research admins.…
- Is the Fundamental Research Exclusion Narrowing? What’s Actually Happened vs. What’s Being Warned
A March 2026 law-firm alert warns the fundamental research exclusion is quietly narrowing for universities. No BIS or Federal Register rule change was found to confirm that framing — here’s what’s act…
- FDA Expedited IND Pilot: Comments Due Aug. 24
FDA’s proposed Expedited IND Pilot Program would speed first-in-human trials via Qualified Research Institutions; comments now due Aug. 24, 2026.…
- FDA’s Real-Time Clinical Trials (RTCT) Pilot: Where It Stands in 2026
FDA has initiated two proof-of-concept real-time clinical trials and opened an RFI on a broader RTCT pilot program. Final selection criteria are expected in July 2026, with pilot selections completed …
- State Dept. Joins Section 117 Foreign-Gift Enforcement
ED’s Feb. 23, 2026 pact with State adds national-security review to Section 117 foreign-gift oversight. Thresholds and deadlines are unchanged.…
- NSPM-33 Research Security Programs: The Real 2026 Deadline, and DoD’s January Memo
NSPM-33’s $50M research security program deadline isn’t one fixed July 2026 date — it’s agency-specific. Plus DoD’s Jan. 2026 memo, explained.…
- Australian Universities Accord Implementation: Where HELP Reform, University Funding, and ATEC Stand in 2026
A 2026 status map of Accord implementation: HELP/HECS reform now law, university funding mid-transition, ATEC on its own legislative track.…
- NSF Research Security: What Notice 149 Requires Proposers to Certify
NSF Notice 149 makes research-security training, MFTRP, and Confucius Institute certifications mandatory for proposals, effective Dec. 2, 2025.…
- NSPM-33 implementation: 18 months in
Eighteen months after NSPM-33 disclosure requirements took effect, a status report on what worked, what is broken, and the institutional adjustments still pending.…
- NSPM-33 disclosure: what US researchers must report in 2026
Current and pending support, foreign-component disclosure, NIH Other Support, foreign-talent-recruitment programmes: the 2026 NSPM-33 compliance landscape.…
